Abstract
Our unbiased preclinical studies have identified vincristine as an effective combination partner for the MEK inhibitor trametinib and provide a novel therapeutic option to be studied in patients with KRAS-mutant colorectal cancer.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have